European patent granted for Toleranzia’s platform technology
28 April - 2016
Toleranzia AB (“Toleranzia “) announces that it has received the European Patent Office’s (EPO’s) approval of patent no. EP2633054, which protects Toleranzia’s tolerogen platform for treatment of autoimmune diseases. This means that the platform technology is protected until 2031 in the European countries in which the company chooses to maintain the patent.
With the EPO’s granting, Toleranzia’s patent is approved in Europe, Australia, China and Japan. The application is in the national phase in the US, Canada and India. As a holder of an approved EPO patent, Toleranzia has full freedom to select within three months the European countries that are considered valuable to maintain the patent in. The company will do this together with its strategic patent agent, HGF Ltd. in the UK.
Current patent protection for the technology platform allows general applicability in autoimmune diseases such as rheumatoid arthritis, multiple sclerosis, type 1 diabetes and myasthenia gravis. In addition, the company’s drug candidate in the autoimmune disease myasthenia gravis previously received orphan drug status in Europe and the US, which provides market exclusivity after marketing for ten years in Europe and seven years in the US.
Charlotte Fribert, CEO, comments:
The fact that we received the EPO’s patent approval is most gratifying and important to us. The approved patent, along with the market exclusivity provided by an orphan drug designation, gives us both an improved product protection and expanded opportunities for commercialization of the platform technology as well as the myasthenia gravis project on key markets.
For further information, please contact:
Charlotte Fribert – CEO
Phone: +46 763 19 98 98
About Toleranzia AB
Toleranzia AB (556877-2866) has developed a platform technology for treatment of autoimmune diseases. The company´s main project is directed towards an autoimmune neuromuscular disease, myasthenia gravis, with a significant need for an effective treatment and an extensive market potential, for which Toleranzia has been granted Orphan Drug Designation in both EU and US. The platform technology enables development of therapies that target the root cause of the disease – not just the symptoms, which is the mainstay of current treatment. In addition to myasthenia gravis, the platform technology has been evaluated in three further disease indications – rheumatoid arthritis, multiple sclerosis and type 1 diabetes, where positive treatment effects have been obtained in disease-relevant animal models. Toleranzia was founded by researchers at the University of Gothenburg. The company has operations at the Biotech center in Gothenburg. Further reading at: www.toleranzia.com.